Caribou Biosciences Inc. (NASDAQ: CRBU) is -17.83% lower on its value in year-to-date trading and has touched a low of $4.89 and a high of $13.19 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRBU stock was last observed hovering at around $5.20 in the last trading session, with the day’s loss setting it -0.04% off its average median price target of $26.00 for the next 12 months. It is also 84.82% off the consensus price target high of $34.00 offered by 5 analysts, but current levels are 72.84% higher than the price target low of $19.00 for the same period.
Currently trading at $5.16, the stock is -14.12% and -21.65% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.61 million and changing -0.77% at the moment leaves the stock -37.24% off its SMA200. CRBU registered -38.72% loss for a year compared to 6-month loss of -58.05%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock witnessed a -23.33% gain in the last 1 month and extending the period to 3 months gives it a -36.76%, and is -12.10% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.42% over the week and 6.13% over the month.
Caribou Biosciences Inc. (CRBU) has around 97 employees, a market worth around $334.78M and $12.70M in sales. Distance from 52-week low is 5.52% and -60.88% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.90%).
Caribou Biosciences Inc. (CRBU) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Caribou Biosciences Inc. (CRBU) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.40, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Caribou Biosciences Inc. is expected to release its quarterly report on 05/08/2023.The EPS is expected to shrink by -83.60% this year
Caribou Biosciences Inc. (CRBU) Top Institutional Holders
The shares outstanding are 60.89M, and float is at 54.41M with Short Float at 7.87%.
Caribou Biosciences Inc. (CRBU) Insider Activity
A total of 5 insider transactions have happened at Caribou Biosciences Inc. (CRBU) in the last six months, with sales accounting for 2 and purchases happening 3 times. The most recent transaction is an insider sale by Rizvi Syed Ali-aamir, the company’s Chief Medical Officer. SEC filings show that Rizvi Syed Ali-aamir sold 5,627 shares of the company’s common stock on Jan 19 at a price of $6.31 per share for a total of $35506.0. Following the sale, the insider now owns 59373.0 shares.
Caribou Biosciences Inc. disclosed in a document filed with the SEC on Oct 06 that Fischesser Ryan (VP of Finance and Controller) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Oct 06 and was made at $10.80 per share for $0.11 million. Following the transaction, the insider now directly holds 0.11 million shares of the CRBU stock.
Still, SEC filings show that on Aug 25, Kanner Steven (Chief Scientific Officer) disposed off 43,248 shares at an average price of $11.22 for $0.49 million. The insider now directly holds 302,059 shares of Caribou Biosciences Inc. (CRBU).
Caribou Biosciences Inc. (CRBU): Who are the competitors?
The company’s main competitors (and peers) include Bristol-Myers Squibb Company (BMY) that is trading -2.54% down over the past 12 months and CRISPR Therapeutics AG (CRSP) that is -22.63% lower over the same period. Intellia Therapeutics Inc. (NTLA) is -30.48% down on the 1-year trading charts.
